BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/25/2020 9:16:00 AM | Browse: 892 | Download: 2269
 |
Received |
|
2020-03-16 09:18 |
|
Peer-Review Started |
|
2020-03-16 09:18 |
|
First Decision by Editorial Office Director |
|
2020-04-26 21:55 |
|
Return for Revision |
|
2020-04-26 21:55 |
|
Revised |
|
2020-05-02 09:40 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2020-06-19 10:06 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-06-20 22:55 |
|
Articles in Press |
|
2020-06-20 22:55 |
|
Edit the Manuscript by Language Editor |
|
2020-06-25 01:54 |
|
Typeset the Manuscript |
|
2020-08-02 12:41 |
|
Publish the Manuscript Online |
|
2020-08-25 09:16 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Areti Sofogianni, Athanasios Filippidis, Lampros Chrysavgis, Konstantinos Tziomalos and Evangelos Cholongitas |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Evangelos Cholongitas, MD, PhD, Associate Professor, First Department of Internal Medicine, Laiko General Hospital, Medical School of National and Kapodistrian University of Athens, Agiou Thoma 17, Athens 11527, Greece. cholongitas@yahoo.gr |
| Key Words |
Glucagon-like peptide-1 receptor agonists; Non-alcoholic fatty liver disease; Type 2 diabetes mellitus; Clinical studies; Fatty liver; Animal studies |
| Core Tip |
The strong relationship between non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) points to a need to evaluate the therapeutic potential of antidiabetic drugs in patients with NAFLD. Accordingly, glucagon-like peptide-1 receptor agonists (GLP-1RAs), which are well-tolerated antidiabetic agents with no risk of hypoglycemia, seem to be a very appealing therapeutic option for T2DM patients with NAFLD. Herein, based on data from animal studies and clinical trials, we discuss the beneficial impact of GLP-1RAs on NAFLD. |
| Publish Date |
2020-08-25 09:16 |
| Citation |
Sofogianni A, Filippidis A, Chrysavgis L, Tziomalos K, Cholongitas E. Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update. World J Hepatol 2020; 12(8): 493-505 |
| URL |
https://www.wjgnet.com/1948-5182/full/v12/i8/493.htm |
| DOI |
https://dx.doi.org/ 10.4254/wjh.v12.i8.493 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
